Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dicerna Pharmaceuticals Inc. DRNA

Healthcare Biotechnology
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.


NDAQ:DRNA - Post by User

Dicerna Pharmaceuticals Inc.
Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by Rhyselliott26on Apr 20, 2018 4:20pm
77 Views
Post# 27919678

Trading and Financial books and or textbooks if interested!

Trading and Financial books and or textbooks if interested!Hi all,

I have trading books and biographies (Pdf versions) including new titles from 2018. If you have college kids, there are also textbooks

I assume people here may be interested in titles pertaining to trading strategies and or biograhies etc I personally have paid up to $150 for the wiley series before.

If you inquire about titles or genres I could help you find what you're looking for. I personally day trade, trade options and have long positions. So i can help you find a title you may be interested in to expand your trading abilities.

These are all pdf's fit for kindle and other e-readers and or computers and phones.

I am not charging for the books but will charge a fee for sending the pdf's to make it worth while.
Prices and conversations can be held at: booksend15@gmail.com

(I can send a book in good faith to assure you that you'll receive you intended title with any payments)
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities